Dan Stinchcomb is the Chief Scientific Officer at IDRI. He began his career in assistant and associate professor roles at Harvard and then moved to senior scientific leadership positions at Synergen Inc. and later Ribozyme Pharmaceuticals Inc., where he served as Director of Biology Research. He then moved into the field of veterinary products at Heska Corp., where he led all aspects of product research and development. In 2005, Dan co-founded and served as President and CEO of Inviragen Inc., which he transformed from a virtual start-up to a global clinical stage company with sites in Colorado, Wisconsin and Singapore and translated two vaccines from the research bench to human clinical trials, including one for dengue fever. In 2013, Inviragen was acquired by Takeda Pharmaceutical Company Limited. Dan also serves as Executive Chair of FluGen, Inc., a biotechnology company developing a novel, single round replicating influenza vaccine. Dan has authored over 50 scientific publications, is an inventor on more than 30 patents and serves as a member of the Vaccines Policy Advisory Committee for BIO, the world’s largest biotechnology trade association. Dan received his PhD from Stanford University and his BA from Harvard College.